

Curriculum vitae

Associate Professor Morten Frier Gjerstorff, Ph.D, DMSc

PROFILE & RESEARCH INTERESTS

Since 2011, I have managed a research group working with translational research in molecular oncology and oncoimmunology. Our main focus is the cellular functions of cancer/testis antigens in tumor cells and clinical application of these proteins as therapeutic targets in immunotherapy of cancer. More recently, we have extended our research to also address the potential use of epigenetic inhibitors in cancer immunotherapy. Our work is anchored at the University of Southern Denmark and Odense University Hospital and carried out in collaboration with national and international partners.

PERSONAL DATA

Born: 1976

Nationality: Danish

Address: J. B. Winsløvs Vej 25, 3., DK-5000 Odense C, Denmark

Phone: +45 21261563

Email: mgjerstorff@health.sdu.dk

CURRENT AND PREVIOUS POSITIONS

2019-present: External consultant, Department of Oncology, Odense University Hospital.

2011-present: Associate professor, Institute for Molecular Medicine, University of Southern Denmark.

2011: Postdoc, Dept. of Antibody Technology, Novo Nordisk A/S, Måløv.

2011: Adjunct associate professor, University of Southern Denmark.

2010 – 2011: Postdoc, Center for Cancer Immune Therapy (CCIT), Herlev hospital.

2010 – 2011: Paternity leave (13 weeks).

2009: Postdoctoral fellow, Johns Hopkins School of Medicine, Baltimore, MD, USA.

2008 – 2009: Postdoc, Medical Biotechnology Center, University of Southern Denmark.

2003: Research assistant, The Scripps Research Institute, La Jolla, CA, USA.

EDUCATION AND ACADEMIC DEGREES

2020: Doctor of Medical Sciences, (dr.med., DMSc), University of Southern Denmark.

2015: Research management course, Copenhagen Business School.

2013: Post graduate teacher training course, University of Southern Denmark.

2008: PhD in Molecular Oncology, University of Southern Denmark (September). PhD supervisor: Professor Henrik Ditzel

2003: M.Sc. in Biomedicine, University of Southern Denmark (January).

SUPERVISOR EXPERIENCE

I have supervised three postdocs, four PhD students, >10 master students and >10 ISA students.

GRANTS & FELLOWSHIPS (>500.000 DKK)

- Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis Legat, 522.000 DKK: Delineating the heterogeneity of epigenetic drug-induced antigen expression for enhanced design of T-cell therapy (2021).
- The Danish Ministry of Health, 1,1 mill DKK (05-0400-41): Delineating the heterogeneity of epigenetic drug-induced antigen expression for enhanced design of T-cell therapy (2020-2021).
- Danish Cancer Society, 937.000 DKK (R1R204-A12255): DNA methyltransferase inhibitors for improved immunotherapy of metastatic breast cancer (2019-2020).
- The Novo Nordisk Foundation, 1.2 mill DKK (NNF18OC0052303): The role of SSX proteins in chromatin remodeling and (epi)genomic reprogramming of cancer cells (2019-2020).
- The Danish Ministry of Health, 1.1 mill DKK (4-1612-236/3): Epigenetic priming of tumors for cellular immunotherapy: a novel approach for treating metastatic breast cancer (2018-2019).
- Danish Cancer Society, 800.000 DKK (R146-A9213-16-S2): The role of SSX2 in regulation of chromatin structure and function in cancer cells (2017-2018).
- The Danish Council for Independent Research – Natural sciences, 1.3 mill DKK (6108-00372A): The role of SSX proteins in chromatin organization (2017-2018).
- The Velux Foundation, 2.3 mill DKK (00009371): Elucidating cellular pathways of senescence: Implications for understanding and treating age-related diseases (2016-2018).
- The Danish Council for Independent Research – Health sciences, 1.95 mill DKK (09-063647): The role of GAGE cancer/testis antigens in microtubule dynamics and cancer (2009-2011).

The applicant has been P.I./main applicant on all grants received. In total, the applicant has independently obtained grants in excess of 13 mill DKK.

MAJOR CURRENT COLLABORATIONS

- Professor Jerome Dejardin, INSERM AVENIR, Institute of Human Genetics, France. Collaboration on the characterization of epigenetic mechanisms of regulation and deregulation of pericentromeric heterochromatin.

- Professor Reno Debets, Erasmus MC Cancer Institute, Netherlands. Collaboration on the development of combination of epigenetic priming and T-cell therapy for cancer treatment.
- Professor Per Thor Straten, Center for Cancer Immune Therapy, Herlev Hospital. Collaboration on the development of novel strategies for T-cell therapy.
- Research Associate Geert Hamer, Amsterdam UMC, Netherlands. Functional genomic screening for identification of oncogenic cancer/testis antigens.
- Docent Fredrik Bergh Thorén, Institute of Biomedicine, University of Gothenburg, Sweden. Collaboration on single-cell sequencing analysis of antigen expression in breast cancer tumors.

COMMISSIONS OF TRUST

- Associate editor on the board of *Frontiers in Oncology*, Molecular and Cellular Oncology section. Responsible for overseeing the review process and making decisions on publication of manuscripts.
- Review of applications for the Dutch research council (2020).
- Member of several assessment committees for scientific personnel at University of Southern Denmark.
- Chairman of 6 PhD assessment committees at University of Southern Denmark.
- Reviewer on 5 PhD assessment committees at University of Copenhagen and Aarhus University.
- Peer review for high-impact international journals including: *Nature Reviews Cancer*, *Science Translational Medicine*, *International Journal of Cancer*, *Cell Death and Disease*, *American Journal of Pathology*, *BBA Reviews on Cancer*.

TEACHING

- Course director and teacher at the PhD course: "Mechanisms and methods in basic cancer biology" (3 ECTS)
- Course director and teacher at the PhD course: "Short introduction to cancer immunology and immunotherapy" (starts 2021) at SDU.
- Course director and teacher at the "Oncology" (5 ECTS) module of the human pathophysiology course for biomedical students (SU810) at SDU.
- Teacher at several courses for medical students: modules B1, B3, B10 and for biomedical students: BMB512.

BOARDS

- Former member of the Gender equality board on University of Southern Denmark.

LIST OF PUBLICATIONS

Peer review publications

- 44: Jakobsen MK, Traynor S, Stæhr M, Duijf PHG, Nielsen AY, Terp MG, Pedersen CB, Guldborg P, Ditzel HJ and **Gjerstorff MF**. The cancer/testis antigen gene *VCX2* is rarely expressed in malignancies but can be epigenetically activated using DNA methyltransferase and histone deacetylase inhibitors. *Front Oncol*. 2020. Accepted, but not yet published. IF=4.9.
- 43: Løkkegaard S, Elias D, Alves CL, Bennetzen MV, Lænkholm A, Bak M, **Gjerstorff MF**, Johansen LE, Vever H, Bjerre C, Kirkegaard T, Nordenskjöld B, Fornander T, Stål O, Lindström LS, Esserman LJ, Lykkesfeldt AE, Andersen JS, Rikke Leth-Larsen R and Ditzel HJ. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. *NPJ Breast Cancer*. 2021 Jan 4;7(1):2. doi: 10.1038/s41523-020-00210-8. PMID: 33398005. IF=6.0.
- 42: **Gjerstorff MF**. Novel insights into epigenetic reprogramming and destabilization of pericentromeric heterochromatin in cancer. *Front Oncol*. 2020 Nov 5;10:594163. doi: 10.3389/fonc.2020.594163. eCollection 2020. PMID: 33251148. IF=4.9.
- 41: Nielsen A, Ormhøj M, Traynor S and **Gjerstorff MF**. Augmenting engineered T-cell strategies in solid cancers through epigenetic priming. *Cancer Immunology, Immunotherapy*. 2020 Jul 10. doi: 10.1007/s00262-020-02661-1. IF=5.4.
- 40: Jakobsen M and **Gjerstorff MF**. CAR T cell cancer therapy targeting surface cancer/testis antigens. *Front Immunol*. 2020 Sep 2;11:1568. doi: 10.3389/fimmu.2020.01568. IF=5.1.
- 39: Mansoori B, Duijf PHG, Mohammadi A, Najafi S, Roshani E, Shanebandi D, Hajiasgharzadeh K, Shirjang S, Ditzel HJ, Kazemi T, Mokhtarzadeh A, **Gjerstorff MF**, Baradaran B. Overexpression of HMG2 in breast cancer promotes cell proliferation, migration, invasion and stemness. *Expert Opin Ther Targets*. 2020 Mar 14:1-11. doi: 10.1080/14728222.2020.1736559. PubMed PMID: 32172636. IF=5.5.
- 38: Johansen S, **Gjerstorff MF**. Interaction between Polycomb and SSX Proteins in Pericentromeric Heterochromatin Function and Its Implication in Cancer. *Cells*. 2020 Jan 16;9(1). pii: E226. doi: 10.3390/cells9010226. Review. PubMed PMID: 31963307. IF=5.6.
- 37: Mansoori B, Mohammadi A, Naghizadeh S, **Gjerstorff M**, Shanebandi D, Shirjang S, Najafi S, Holmskov U, Khaze V, Duijf PHG, Baradaran B. miR-330 suppresses EMT and induces apoptosis by downregulating HMG2 in human colorectal cancer. *J Cell Physiol*. 2020 Feb;235(2):920-931. doi: 10.1002/jcp.29007. Epub 2019 Jun 26. PubMed PMID: 31241772. IF=5.5.

- 36: Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Christensen JH, **Gjerstorff MF**, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. *Clin Cancer Res*. 2019 Dec 1;25(23):7046-7057. doi: 10.1158/1078-0432.CCR-19-1337. Epub 2019 Aug 22. PubMed PMID: 31439577. IF=10.2.
- 35: Brückmann NH, Bennedsen SN, Duijf PHG, Terp MG, Thomassen M, Larsen M, Pedersen CB, Kruse T, Alcaraz N, Ditzel HJ, **Gjerstorff MF**. A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence. *Cell Death Dis*. 2019 Nov 6;10(11):841. doi: 10.1038/s41419-019-2068-1. PubMed PMID: 31695025. IF=6.3.
- 34: Traynor S, Møllegaard NE, Jørgensen MG, Brückmann NH, Pedersen CB, Terp MG, Johansen S, Dejardin J, Ditzel HJ, **Gjerstorff MF**. Remodeling and destabilization of chromosome 1 pericentromeric heterochromatin by SSX proteins. *Nucleic Acids Res*. 2019 Jul 26;47(13):6668-6684. doi: 10.1093/nar/gkz396. PubMed PMID: 31114908. IF=11.6.
- 33: Asadi M, Talesh ST, **Gjerstorff MF**, Shanehbandi D, Baradaran B, Hashemzadeh S, Zafari V. Identification of miRNAs correlating with stage and progression of colorectal cancer. *Future Med*. 2019 Nov 4;8(2). IF=2.3.
- 32: Shirjang S, Mansoori B, Asghari S, Duijf PHG, Mohammadi A, **Gjerstorff M**, Baradaran B. MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis. *Free Radic Biol Med*. 2019 Aug 1;139:1-15. doi: 10.1016/j.freeradbiomed.2019.05.017. Epub 2019 May 15. Review. Erratum in: *Free Radic Biol Med*. 2020 Jan;146:402. PubMed PMID: 31102709. IF=6.0.
- 31: Mansoori B, Mohammadi A, Asadzadeh Z, Shirjang S, Minouei M, Abedi Gaballu F, Shajari N, Kazemi T, **Gjerstorff MF**, Duijf PHG, Baradaran B. HMGA2 and Bach-1 cooperate to promote breast cancer cell malignancy. *J Cell Physiol*. 2019 Aug;234(10):17714-17726. doi: 10.1002/jcp.28397. Epub 2019 Mar 1. PubMed PMID: 30825204. IF=5.5.
- 30: Mansoori B, Mohammadi A, Ghasabi M, Shirjang S, Dehghan R, Montazeri V, Holmskov U, Kazemi T, Duijf P, **Gjerstorff M**, Baradaran B. miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression. *J Cell Physiol*. 2019 Jun;234(6):9816-9825. doi: 10.1002/jcp.27670. Epub 2018 Nov 27. PubMed PMID: 30480817. IF=5.5.
- 29: Mansoori B, Mohammadi A, Amin Doustvandi M, Mohammadnejad F, Kamari F, **Gjerstorff MF**, Baradaran B, Hamblin MR. Photodynamic therapy for cancer: Role of natural products. *Photodiagnosis Photodyn Ther*. 2019 Jun;26:395-404. doi: 10.1016/j.pdpdt.2019.04.033. Epub 2019 May 4. Review. PubMed PMID: 31063860. IF=2.9.
- 28: Mansoori B, Mohammadi A, **Gjerstorff MF**, Shirjang S, Asadzadeh Z, Khaze V, Holmskov U, Kazemi T, Duijf PHG, Baradaran B. miR-142-3p is a tumor suppressor that inhibits estrogen receptor expression in ER-positive breast cancer. *J Cell Physiol*. 2019 Feb 11. doi: 10.1002/jcp.28263. [Epub ahead of print] PubMed PMID: 30741415. IF=5.5.
- 27: Hansen SV, Traynor S, Ditzel HJ, **Gjerstorff MF**. Human DREF/ZBED1 is a nuclear protein widely expressed in multiple cell types derived from all three primary germ layers. *PLoS One*. 2018 Oct 10;13(10):e0205461. doi: 10.1371/journal.pone.0205461. eCollection 2018. PubMed PMID: 30304065. IF=2.8.
- 26: Kirkin AF, Dzhandzhugazyan KN, Guldborg P, Fang JJ, Andersen RS, Dahl C, Mortensen J, Lundby T, Wagner A, Law I, Broholm H, Madsen L, Lundell-Ek C, **Gjerstorff MF**, Ditzel HJ, Jensen MR, Fischer W. Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. *Nat Commun*. 2018 Mar 6;9(1):785. doi: 10.1038/s41467-018-03217-9. PubMed PMID: 29511178. IF=12.1.
- 25: Brückmann NH, Pedersen CB, Ditzel HJ, **Gjerstorff MF**. Epigenetic Reprogramming of Pericentromeric Satellite DNA in Premalignant and Malignant Lesions. *Mol Cancer Res*. 2018 Mar;16(3):417-427. doi: 10.1158/1541-7786.MCR-17-0477. Epub 2018 Jan 12. PubMed PMID: 29330295. IF=5.0.
- 24: Nielsen AY, **Gjerstorff MF**. Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability. *Int J Mol Sci*. 2016 Jun 6;17(6). pii: E890. doi: 10.3390/ijms17060890. Review. PubMed PMID: 27275820. IF=3.1.
- 23: **Gjerstorff MF**, Terp MG, Hansen MB, Ditzel HJ. The role of GAGE cancer/testis antigen in metastasis: the jury is still out. *BMC Cancer*. 2016 Jan 8;16:7. doi: 10.1186/s12885-015-1998-y. PubMed PMID: 26747105; PubMed Central PMCID: PMC4706694. IF=3.3.
- 22: Maheswaran E, Pedersen CB, Ditzel HJ, **Gjerstorff MF**. Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer. *PLoS One*. 2015 Aug 7;10(8):e0134967. doi: 10.1371/journal.pone.0134967. eCollection 2015. PubMed PMID: 26252478. IF=3.2.
- 21: **Gjerstorff MF**, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. *Oncotarget*. 2015 Jun 30;6(18):15772-87. doi: 10.18632/oncotarget.4694. PMID: 26158218. IF=6.3.

- 20: Elias D, Vever H, Lænkholm AV, **Gjerstorff MF**, Yde CW, Lykkesfeldt AE, Ditzel HJ. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. *Oncogene*. 2015 Apr 9;34(15):1919-27. doi: 10.1038/onc.2014.138. Epub 2014 Jun 2. Erratum in: *Oncogene*. 2018 Oct;37(41):5585-5586. PubMed PMID: 24882577. IF=8.5.
- 19: Greve KB, Lindgreen JN, Terp MG, Pedersen CB, Schmidt S, Mollenhauer J, Kristensen SB, Andersen RS, Relster MM, Ditzel HJ, **Gjerstorff MF**. Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. *Mol Oncol*. 2015 Feb;9(2):437-49. doi: 10.1016/j.molonc.2014.09.001. Epub 2014 Oct 6. PubMed PMID: 25363656; PubMed Central PMCID: PMC5528659. IF=6.2.
- 18: **Gjerstorff MF**, Relster MM, Greve KB, Moeller JB, Elias D, Lindgreen JN, Schmidt S, Mollenhauer J, Voldborg B, Pedersen CB, Brückmann NH, Møllegaard NE, Ditzel HJ. SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression. *Nucleic Acids Res*. 2014 Oct;42(18):11433-46. doi: 10.1093/nar/gku852. Epub 2014 Sep 23. PubMed PMID: 25249625. IF=9.1.
- 17: Greve KB, Pøhl M, Olsen KE, Nielsen O, Ditzel HJ, **Gjerstorff MF**. SSX2-4 expression in early-stage non-small cell lung cancer. *Tissue Antigens*. 2014 May;83(5):344-9. doi: 10.1111/tan.12340. Epub 2014 Mar 20. PubMed PMID: 24645645. IF=3.2.
- 16: **Gjerstorff MF**, Pøhl M, Olsen KE, Ditzel HJ. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. *BMC Cancer*. 2013 Oct 8;13:466. doi: 10.1186/1471-2407-13-466. PubMed PMID: 24103781; PubMed Central PMCID: PMC3851761. IF=3.3.
- 15: **Gjerstorff MF**, Ditzel HJ. Limited SP17 expression within tumors diminishes its therapeutic potential. *Tissue Antigens*. 2012 Dec;80(6):523-7. doi: 10.1111/tan.12015. PubMed PMID: 23137323. IF=3.1.
- 14: **Gjerstorff MF**, Rösner HI, Pedersen CB, Greve KB, Schmidt S, Wilson KL, Mollenhauer J, Besir H, Poulsen FM, Møllegaard NE, Ditzel HJ. GAGE cancer-germline antigens are recruited to the nuclear envelope by germ cell-less (GCL). *PLoS One*. 2012;7(9):e45819. doi: 10.1371/journal.pone.0045819. Epub 2012 Sep 20. PubMed PMID: 23029259; PubMed Central PMCID: PMC3447759. IF=4.6.
- 13: Schoennemann KR, Bjerregaard JK, Hansen TP, De Stricker K, **Gjerstorff MF**, Jensen HA, Vestermark LW, Pfeiffer P. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. *Gastric Cancer*. 2011 Aug;14(3):219-25. doi: 10.1007/s10120-011-0031-7. Epub 2011 Mar 17. PubMed PMID: 21409520. IF=3.5.
- 12: **Gjerstorff MF**, Besir H, Larsen MR, Ditzel HJ. Expression, purification and characterization of the cancer-germline antigen GAGE121: a candidate for cancer immunotherapy. *Protein Expr Purif*. 2010 Oct;73(2):217-22. doi: 10.1016/j.pep.2010.05.010. Epub 2010 May 27. PubMed PMID: 20546897. IF=1.5.
- 11: **Gjerstorff MF**, Burns J, Ditzel HJ. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment. *Expert Opin Biol Ther*. 2010 Jul;10(7):1061-75. doi: 10.1517/14712598.2010.485188. Review. PubMed PMID: 20420535. IF=3.9.
- 10: **Gjerstorff M**, Burns JS, Nielsen O, Kassem M, Ditzel H. Epigenetic modulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy. *Am J Pathol*. 2009 Jul;175(1):314-23. doi: 10.2353/ajpath.2009.080893. Epub 2009 Jun 4. PubMed PMID: 19498007. IF=5.7.
- 9: **Gjerstorff MF**, Harkness L, Kassem M, Frandsen U, Nielsen O, Lutterodt M, Møllgård K, Ditzel HJ. Distinct GAGE and MAGE-A expression during early human development indicate specific roles in lineage differentiation. *Hum Reprod*. 2008 Oct;23(10):2194-201. doi: 10.1093/humrep/den262. Epub 2008 Jul 8. PubMed PMID: 18611917. IF=4.6.
- 8: **Gjerstorff MF**, Ditzel HJ. An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. *Tissue Antigens*. 2008 Mar;71(3):187-92. doi: 10.1111/j.1399-0039.2007.00997.x. Epub 2008 Jan 7. Review. PubMed PMID: 18179644. IF=3.1.
- 7: Hansen S, Schmidt V, Steffensen MA, Jensen PH, **Gjerstorff M**, Thiel S, Holmskov U. An enzyme-linked immunosorbent assay (ELISA) for quantification of mouse surfactant protein D (SP-D). *J Immunol Methods*. 2008 Jan 31;330(1-2):75-85. Epub 2007 Nov 29. PubMed PMID: 18078951. IF=1.8.
- 6: **Gjerstorff MF**, Kock K, Nielsen O, Ditzel HJ. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. *Hum Reprod*. 2007 Apr;22(4):953-60. Epub 2007 Jan 5. PubMed PMID: 17208940. IF=4.6.
- 5: **Gjerstorff MF**, Johansen LE, Nielsen O, Kock K, Ditzel HJ. Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. *Br J Cancer*. 2006 Jun 19;94(12):1864-73. doi: 10.1038/sj.bjc.6603163. PMID: 16773077. IF=4.8.

4: **Gjerstorff MF**, Benoit VM, Laenkholm AV, Nielsen O, Johansen LE, Ditzel HJ. Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. *Int J Oncol.* 2006 Jun;28(6):1327-35. PubMed PMID: 16685433. IF=3.2.

3: **Gjerstorff M**, Hansen S, Jensen B, Dueholm B, Horn P, Bendixen C, Holmskov U. The genes encoding bovine SP-A, SP-D, MBL-A, conglutinin, CL-43 and CL-46 form a distinct collectin locus on *Bos taurus* chromosome 28 (BTA28) at position q.1.8-1.9. *Anim Genet.* 2004 Aug;35(4):333-7. PubMed PMID: 15265076. IF=2.3.

2: **Gjerstorff M**, Madsen J, Bendixen C, Holmskov U, Hansen S. Genomic and molecular characterization of bovine surfactant protein D (SP-D). *Mol Immunol.* 2004 Jun;41(4):369-76. PubMed PMID: 15163533. IF=3.0.

1: **Gjerstorff M**, Dueholm B, Bendixen C, Holmskov U, Hansen S. Assignment of the surfactant protein A gene (SFTPA) to bovine chromosome 28q1.8-->q1.9 by radiation hybrid mapping. *Cytogenet Genome Res.* 2004;106(1):142. PubMed PMID: 15222309. IF=1.6.

Book chapters

Ditzel H, **Gjerstorff M**. GAGE proteins. *Encyclopedia of Cancer*, second edition, Ed. Manfred Schwab, Springer, 2008.

Ditzel H, **Gjerstorff M**. GAGE proteins. *Encyclopedia of Cancer*, fourth edition, Ed. Manfred Schwab, Springer, 2008.

Publications without peer-review

Gjerstorff MF. Cancer/testis proteiners rolle i kræftudvikling og behandling. *Best Practice*, October, 2016.